GlassScriptPhysician profile
Henry Van Gieson
NPI 1669403549
$14,539.50
in general payments reported to CMS, 2019-2025
50 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,881 · 2020: $1,467 · 2021: $1,811 · 2022: $2,708 · 2023: $2,597 · 2024: $1,621 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,671.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,617.01 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,388.42 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,250.56 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,245.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,026.01 | 2019-2025 | Farxiga, Brilinta |
| Medtronic Vascular, INC. | $1,001.70 | 2019-2020 | |
| Amgen INC. | $867.49 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $604.69 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $600.12 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $496.24 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $483.96 | 2019-2025 | Lifevest |
| Medtronic, INC. | $443.64 | 2021-2025 | Pulseselect, Micra |
| Abbott Laboratories | $369.55 | 2021-2024 | Mitraclip, Cardiomems |
| Esperion Therapeutics, INC. | $284.77 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $250.79 | 2019-2025 | Watchman Flx, Sentinel, Watchman Access System |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Van Gieson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.